Target and the Target Foundation have made made big gifts to groups working on Black economic empowerment and LGBTQ+ ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

StockNews.com upgraded shares of Xerox (NYSE:XRX – Free Report) from a hold rating to a buy rating in a report issued on Tuesday morning. Several other research analysts also recently commented on XRX ...

Until you do better, we’re putting a pause on our Target habits.

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Barclays analyst Brandt Montour lowered the firm’s price target on Las Vegas Sands (LVS) to $58 from $61 and keeps an Overweight rating on the ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares. The company provided a “robust defense” of its Q4 ...

On Wednesday, Wells Fargo (NYSE:WFC) reiterated its Overweight rating and $1,000.00 price target on Eli Lilly (NYSE:NYSE:LLY) shares despite the pharmaceutical company's fourth-quarter revenue falling ...

Last year featured slower merger and acquisition (M&A) activity than 2023 and a moderate uptick in alliances. Here, we highlight the trends and key deals. The transactions analysed include those ...